Kleo Pharmaceuticals was awarded the inaugural $50K Innovation Prize sponsored by Boehringer Ingelheim and Boehringer Ingelheim Venture Fund as recognition of its work in developing small molecule immunotherapies.
New Haven, CT - December 31, 2015
Kleo Pharmaceuticals Inc (Kleo). a biotechnology company pioneering a new class of small molecule immunotherapies, won the inaugural $50K Innovation Prize at the partnering day event hosted at Massachusetts Biotechnology Council (MassBio), and sponsored by Boehringer Ingelheim (BI) and Boehringer Ingelhiem Venture Fund (BIVF). Kleo was one of 15 early stage companies selected to present and compete at the event, which was attended by more than 200 industry and academic innovators in the life sciences. Attendees voted to determine the top five companies with the most technologies and the winner was selected from that group by a panel of BI and BIVF professionals.
"We are thrilled to be part of such a vibrant biotech community," said Dr. David Spiegel, Kleo's founder, "It's a great honor to be recognized by BI and BIVF for the work that has been done and what we are setting out to do with small molecule immunotherapies. We look forward to advancing our technology to the clinic and building a collaborative relationship with the industry. Many thanks to all who participated."
About Kleo Pharmaceuticals
Kleo Pharmaceuticals Inc. is creating a new class of drugs utilizing small molecules as targeted immunotherapies. The molecules, called Antibody Recruiting Molecules (ARMs) and Synthetic Antibody Mimics (SyAMs) are bifunctional small molecules that can recruit the immune system to target and kill specific disease-causing cells. The company's technology is built on the research of Dr. David Spiegel, MD, PhD of Yale University and has primary application in oncology indications as well as potential in infectious diseases.
Kleo Pharmaceuticals, Inc.